Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Scottsdale Research Institute

Also known as: SRI

1 Drug Candidate

Scottsdale Research Institute (SRI) is an Arizona-based research organization conducting the world's first controlled clinical trial of whole psilocybin mushrooms. Their FDA-approved Phase 1 study tests naturally-grown whole mushrooms (30mg psilocybin dose) for PTSD in first responders and military veterans, funded by $5M from the Arizona Legislature. The study explores the entourage effect hypothesis compared to isolated synthetic psilocybin. Led by Dr. Sue Sisley.

Drug Pipeline

1

Whole Psilocybin Mushroom

Psilocybin
Phase I
PTSD

Whole dried psilocybin mushrooms standardised to 30mg psilocybin (~4.5g whole mushroom). First-in-kind controlled trial. Phase 1 for PTSD in firefighters, police, and military veterans. Arizona state-funded ($5M). FDA-approved IND. DEA-licensed facility.

Quick Facts

Type
Non-Profit
Lead Stage
Phase I
Website
Visit